![](/img/cover-not-exists.png)
Onartuzumab with or without bevacizumab in combination with weekly paclitaxel does not prolong QTc or adversely affect other ECG parameters in patients with locally recurrent or metastatic triple-negative breast cancer
Borin, Marie T., Chen, Meng, Mocci, Simonetta, Rubets, Igor, Chittenden, Jason, Aldairy, Wassim, Stroh, MarkVolume:
75
Language:
english
Journal:
Cancer Chemotherapy and Pharmacology
DOI:
10.1007/s00280-014-2652-0
Date:
February, 2015
File:
PDF, 1.04 MB
english, 2015